Codexis Announces New Employment Inducement Grants
Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, has announced the approval of equity grants to eight new employees. The grants, approved by the Compensation Committee of Codexis' Board of Directors, include:
1. Options to purchase 350,175 shares of Codexis common stock
2. 80,138 restricted stock units (RSUs) as inducement awards
Notably, these grants include equity awards for Codexis' newly appointed Chief Financial Officer, Georgia Erbez, who received:
- An option to purchase 300,000 shares of Company common stock
- 50,000 shares of RSUs
The stock options have an exercise price equal to the closing price per share of Codexis' common stock as reported by Nasdaq on the grant date. They vest over four years, with 25% vesting on the first anniversary and the remainder vesting monthly thereafter. The RSUs vest in equal annual installments over three years.
Codexis, Inc. (NASDAQ: CDXS), un fornitore leader di soluzioni enzimatiche per la produzione di farmaci efficienti e scalabili, ha annunciato l'approvazione di concessioni azionarie a otto nuovi dipendenti. Le concessioni, approvate dal Comitato per la Compensazione del Consiglio di Amministrazione di Codexis, includono:
1. Opzioni per l'acquisto di 350.175 azioni comuni di Codexis
2. 80.138 unità di azioni vincolate (RSU) come premi d'induzione
È importante notare che queste concessioni includono premi azionari per la nuova Direttrice Finanziaria, Georgia Erbez, che ha ricevuto:
- Un'opzione per acquistare 300.000 azioni delle azioni comuni della Società
- 50.000 azioni di RSU
Le opzioni su azioni hanno un prezzo di esercizio pari al prezzo di chiusura per azione delle azioni comuni di Codexis come riportato da Nasdaq nella data della concessione. Si maturano su quattro anni, con il 25% che matura al primo anniversario e il resto che matura mensilmente da allora. Le RSU maturano in rate annuali uguali nell'arco di tre anni.
Codexis, Inc. (NASDAQ: CDXS), un proveedor líder de soluciones enzimáticas para la fabricación de terapias eficientes y escalables, ha anunciado la aprobación de concesiones de acciones a ocho nuevos empleados. Las concesiones, aprobadas por el Comité de Compensación de la Junta Directiva de Codexis, incluyen:
1. Opciones para comprar 350,175 acciones comunes de Codexis
2. 80,138 unidades de acciones restringidas (RSUs) como premios de inducción
Es notable que estas concesiones incluyen premios de acciones para la recién nombrada Directora Financiera, Georgia Erbez, quien recibió:
- Una opción para comprar 300,000 acciones de acciones comunes de la Compañía
- 50,000 acciones de RSUs
Las opciones sobre acciones tienen un precio de ejercicio igual al precio de cierre por acción de las acciones comunes de Codexis según lo informado por Nasdaq en la fecha de la concesión. Se consolidan durante cuatro años, con un 25% consolidándose en el primer aniversario y el resto consolidándose mensualmente a partir de entonces. Las RSUs se consolidan en cuotas anuales iguales durante tres años.
Codexis, Inc. (NASDAQ: CDXS), 효율적이고 확장 가능한 치료제 제조를 위한 효소 솔루션의 선도 공급업체가 여덟 명의 신규 직원에 대한 주식 보조금을 승인했다고 발표했습니다. 이 보조금은 Codexis 이사회 보상 위원회에서 승인한 것으로, 다음과 같은 내용을 포함합니다:
1. Codexis 보통주 350,175주 매수 옵션
2. 유인상으로 제공된 80,138 제한 주식 단위 (RSU)
특히, 이러한 보조금에는 새로 임명된 최고 재무 책임자 Georgia Erbez에 대한 주식 보조금이 포함되어 있습니다. Georgia는 다음과 같은 내용을 받았습니다:
- 회사 보통주 300,000주 매수 옵션
- 50,000주 RSU
주식 옵션의 행사 가격은 보조금 부여일에 Nasdaq에서 보고한 Codexis 보통주의 종가와 같습니다. 옵션은 4년에 걸쳐 보유되며, 첫 번째 기념일에 25%가 보유되고 그 이후로는 매월 보유됩니다. RSU는 3년에 걸쳐 동등한 연간 할부로 보유됩니다.
Codexis, Inc. (NASDAQ: CDXS), un fournisseur leader de solutions enzymatiques pour la fabrication de thérapies efficaces et évolutives, a annoncé l'approbation de concessions d'actions à huit nouveaux employés. Les concessions, approuvées par le Comité de Rémunération du Conseil d'Administration de Codexis, comprennent :
1. Options d'achat de 350,175 actions ordinaires de Codexis
2. 80,138 unités d'actions restreintes (RSUs) en tant que récompenses d'incitation
Il convient de noter que ces concessions comprennent des récompenses d'actions pour la nouvelle Directrice financière, Georgia Erbez, qui a reçu :
- Une option d'achat de 300,000 actions ordinaires de la société
- 50,000 actions de RSUs
Les options sur actions ont un prix d'exercice égal au prix de clôture par action des actions ordinaires de Codexis tel que rapporté par Nasdaq à la date de concession. Elles s'acquièrent sur quatre ans, avec 25 % s'acquérant à la première anniversary et le reste s'acquérant mensuellement par la suite. Les RSUs s'acquièrent par des versements annuels égaux sur trois ans.
Codexis, Inc. (NASDAQ: CDXS), ein führender Anbieter von enzymatischen Lösungen für eine effiziente und skalierbare Herstellung therapeutischer Produkte, hat die Genehmigung von Aktienzuwendungen an acht neue Mitarbeiter bekannt gegeben. Die Zuwendungen wurden vom Vergütungsausschuss des Vorstandes von Codexis genehmigt und beinhalten:
1. Optionen zum Kauf von 350.175 Aktien von Codexis-Stammaktien
2. 80.138 eingeschränkte Aktieneinheiten (RSUs) als Anreizprämien
Bemerkenswert ist, dass diese Zuwendungen Aktienauszeichnungen für die neuernannte Finanzvorständin Georgia Erbez beinhalten, die erhielt:
- Eine Option zum Kauf von 300.000 Aktien der Stammaktien des Unternehmens
- 50.000 Aktien in Form von RSUs
Die Aktienoptionen haben einen Ausübungspreis, der dem Schlusskurs pro Aktie der Codexis-Stammaktien entspricht, wie er von Nasdaq am Zuwendungsdatum berichtet wurde. Sie werden über vier Jahre fällig, wobei 25% am ersten Jahrestag und der Rest anschließend monatlich fällig wird. Die RSUs werden über drei Jahre in gleichen jährlichen Raten fällig.
- Appointment of a new Chief Financial Officer, Georgia Erbez
- Expansion of the team with eight new employees
- Implementation of equity-based compensation to attract and retain talent
- Potential dilution of existing shareholders due to the issuance of new equity grants
REDWOOD CITY, Calif., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the approval of equity grants to eight new employees as approved by the Compensation Committee of Codexis’ Board of Directors. The newly hired employees received equity awards consisting of an aggregate of (i) options to purchase 350,175 shares of Codexis common stock and (ii) 80,138 restricted stock units (RSUs) as inducement awards under the company’s 2024 Inducement Plan. Included in this total are equity awards for Codexis’ newly appointed Chief Financial Officer, Georgia Erbez. As part of her inducement to commence employment, Ms. Erbez was granted an option to purchase 300,000 shares of Company common stock and 50,000 shares of RSUs.
The stock options have an exercise price equal to the closing price per share of Codexis’ common stock as reported by Nasdaq on the grant date, and vest over four years, with 25 percent of the shares vesting on the first anniversary of the vesting commencement date, and the remainder vesting ratably at the end of each subsequent month thereafter, subject to each employee’s continued service with Codexis through the applicable vesting dates. The RSUs will vest in equal annual installments on each anniversary of the grant date, until the third anniversary of such date, subject to each employee’s continued service with Codexis through the applicable vesting dates.
Codexis is providing this information in accordance with Nasdaq Listing Rule 5635(c)4.
About Codexis
Codexis is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, leveraging its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes and other classes of proteins. Codexis enzymes solve for real-world challenges associated with small molecule and nucleic acid therapeutics manufacturing. The Company is currently developing its proprietary ECO Synthesis™ manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit www.codexis.com.
For More Information
Investor Contact
Carrie McKim
(336) 608-9706
ir@codexis.com
Media Contact
Lauren Musto
(650) 421-8205
media@codexis.com
FAQ
What equity grants did Codexis (CDXS) announce for new employees?
What equity grants did Codexis (CDXS) provide to its new CFO, Georgia Erbez?
How do the stock options vest for new employees at Codexis (CDXS)?
What is the vesting schedule for RSUs granted to new Codexis (CDXS) employees?
